FDA approval for novel breast cancer drug granted ahead of anticipated target date
the ONA take:
The US Food and Drug Administration granted accelerated approved for palbociclib (Ibrance) for the treatment of advanced breast cancer in postmenopausal women whose tumors do not express HER2 protein.
Palbociclib blocks molecules linked to cancer cell growth; it is intended for use in combination with letrozole. Designated as a breakthrough drug in 2014, approval was granted 2 months ahead of its April 13 target date. A 165-patient study showed that palbociclib slowed the progression of breast cancer.
Patients taking palbociclib and letrozole lived 20.2 months on average before their tumors worsened. The most common side effects reported were low white blood cell count, fatigue, nausea, hair loss, diarrhea, vomiting, and nerve damage. The drug is manufactured by Pfizer Inc.
The FDA granted accelerated approved for palbociclib (Ibrance) for the treatment of advanced breast cancer.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- Hydroxyurea May Improve Kidney Function in PV-Associated Nephrotic Syndrome
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Study Identifies Factors Associated With Infection-related Complications in ALL
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- New Recommendations for Secondary Prevention of Cervical Cancer
- Nonadherence to Posttreatment Imaging Follow-up Common Among Breast Cancer Survivors
- HIIT Improves Cardiorespiratory Fitness in Patients With Resectable NSCLC
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|